

August 25, 2023

Τo

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza,

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

MUMBAI -400 001

**BSE LIMITED** 

Tο

Company Code No. AUROPHARMA

Company Code No. 524804

Phiroz Jeejeebhoy Towers,

25th floor, Dalal Street,

The Corporate Relations Department

Dear Sir/Madam,

Sub: News Clarification - Reg.,

Ref: News Article in The Economic Times - Aurobindo puts its injectables business on the block, again.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015 (Listing Regulations), we hereby clarify as under on the aforesaid article:

- The Company has already informed the Stock Exchanges on August 12, 2023, as part of outcome of its Board meeting that it is in the process of exploring all the possibilities of restructuring of the business of Eugia Pharma Specialities Limited, a wholly owned subsidiary company focused on sterile / injectables, oncology and hormonal products.
- And as stated earlier, the Committee of Independent Directors will pursue a comprehensive evaluation of
  various alternatives or options and recommend to the Board for engendering the next horizon of growth as
  also enhancing value creation to the stakeholders.

The Company will make appropriate disclosure in compliance with the Listing Regulations as and when any such requirement arises.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

## **AUROBINDO PHARMA LIMITED**

(CIN: L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H